Subcutaneous belimumab in the treatment of systemic lupus erythematosus

Keyphrases

• Systemic Lupus Erythematosus 100%
• Belimumab 100%
• Kidney 33%
• Targeted Drugs 33%
• Cardiovascular System 33%
• Clinical Manifestations 33%
• Adverse Events 33%
• Central Nervous System 33%
• Peripheral Nervous System 33%
• Biological Drugs 33%
• Lupus 33%
• Organ Involvement 33%
• US FDA 33%
• Health Canada 33%
• Chronic Autoimmune Disease 33%
• Immunosuppressive Medications 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Systemic Lupus Erythematosus 100%
• Belimumab 100%
• Diseases 66%
• Adverse Event 33%
• Autoimmune Disease 33%
• Glucocorticoid 33%
• Immunosuppressive Agent 33%
• Antimalarial Agent 33%

Immunology and Microbiology

• Systemic Lupus Erythematosus 100%
• Belimumab 100%
• Immunosuppressive Drug 33%
• Central Nervous System 33%
• Autoimmune Disease 33%
• Peripheral Nervous System 33%
• Lupus Erythematosus 33%
• Glucocorticoid 33%
• Cardiovascular System 33%